Spots Global Cancer Trial Database for egfr exon 19 deletion

Every month we try and update this database with for egfr exon 19 deletion cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy	NCT05338970	Nonsquamous Non... EGFR L858R EGFR Exon 19 De...	Patritumab Deru... Platinum-based ...	18 Years -	Daiichi Sankyo
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy	NCT05338970	Nonsquamous Non... EGFR L858R EGFR Exon 19 De...	Patritumab Deru... Platinum-based ...	18 Years -	Daiichi Sankyo
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation
Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)	NCT05998993	EGF-R Positive ... Non Small Cell ... EGFR Exon 19 De... EGFR Exon 21 Mu... EGFR G719X	Stereotactic Bo...	18 Years - 99 Years	Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC	NCT05153408	Lung Neoplasm Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR C797S EGFR C797A EGFR L858R EGFR Exon 19 De... EGFR Gene Mutat... EGF-R Positive ... EGFR Mutation R... EGFR Activating... Thoracic Neopla... Antineoplastic ... Protein Kinase ... EGFR C797G EGFR C797X Non Small Cell ...	BLU-701 osimertinib carboplatin pemetrexed	18 Years -	Blueprint Medicines Corporation
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC	NCT04862780	Lung Neoplasms Carcinoma, Non-... Respiratory Tra... Neoplasms Neoplasms by Si... Lung Diseases Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Adenocarcinoma Carcinoma Neoplasms by Hi... Neoplasms, Nerv... EGFR T790M EGFR C797S EGFR L858R EGFR Gene Mutat... EGF-R Positive ... EGFR Exon 19 De... EGFR Mutation R... EGFR Activating... Protein Kinase ... Antineoplastic ... Thoracic Neopla...	BLU-945 osimertinib	18 Years -	Blueprint Medicines Corporation

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: